Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 17/2003

01.12.2003 | Review Article

Economic implications of attention-deficit hyperactivity disorder for healthcare systems

verfasst von: Dr Cynthia L. Leibson, Kirsten Hall Long

Erschienen in: PharmacoEconomics | Ausgabe 17/2003

Einloggen, um Zugang zu erhalten

Abstract

Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic conditions of childhood, with adverse consequences that persist through adolescence into adulthood. Thus, the burden of illness associated with ADHD is high for affected individuals, their families, and society at large. This article reviews available information about ADHD-associated utilisation of healthcare resources, direct medical costs, and the costs or cost effectiveness of pharmacological interventions.
Published estimates suggest that direct medical costs for youth with ADHD are approximately double those for youth without ADHD. Cross-sectional studies suggest that ADHD-associated incremental costs are highest for mental health services and pharmaceutical costs, and are greatest for youth with comorbid psychiatric conditions and for those being treated with stimulant medication. To guide relevant clinical and health policy, additional research is warranted on the following: source of increased costs observed among persons with ADHD; patient characteristics of those accruing high medical costs; and the long-term effect of ADHD treatment on direct and indirect costs.
Literatur
1.
Wokaich ML. Attention deficit hyperactivity disorder: the most studied and yet most controversial diagnosis. Ment Retard Dev Disabil Res Rev 1999; 5: 163–8CrossRef
2.
Barbaresi W, Katusic SK, Colligan RC, et al. How common is attention-deficit/hyperactivity disorder?: incidence in a popu-lation-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med 2002; 156: 217–24PubMed
3.
Sawyer MG, Arney FM, Baghurst PA, et al. The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being. Aust N Z J Psychiatry 2001; 35: 806–14PubMedCrossRef
4.
Angold A, Erkanli A, Egger HL, et al. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 2000; 39: 975–84PubMedCrossRef
5.
Jensen PS, Kettle L, Roper MT, et al. Are stimulants over-prescribed?: treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 1999; 38: 797–804PubMedCrossRef
6.
Pineda D, Ardila A, Rossetti M, et al. Prevalence of attention-deficit/hyperactivity disorder symptoms in 4- to 17-year-old children in the general population. J Abnorm Child Psychol 1999; 27: 455–62PubMedCrossRef
7.
Rowland AS, Umbach DM, Catoe KE, et al. Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results. Can J Psychiatry 2001; 46: 931–40PubMed
8.
Wokaich ML, Hannah IN, Pinnock TY, et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996; 35: 319–24CrossRef
9.
Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 1995; 34: 629–38PubMedCrossRef
10.
Abikoff HB, Jensen PS, Arnold LLE, et al. Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol 2002; 30: 349–59PubMedCrossRef
11.
Rohde LA, Biederman J, Busnello EA, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. J Am Acad Child Adolesc Psychiatry 1999; 38: 716–22PubMedCrossRef
12.
Brock SW, Knapp PK. Reading comprehension abilities of children with attention-deficit/hyperactivity disorder. J Allen Disord 1996; 1: 173–86CrossRef
13.
Casey JE, Rourke BP, Del Dotto JE. Learning disabilities in children with attention deficit disorder with and without hyper-activity. Neuropsychol Dev Cogn Sect C Child Neuropsychol 1996; 2: 83–98
14.
Barkley RA, Anastopoulos AD, Guevremont DC, et al. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization. J Am Acad Child Adolesc Psychiatry 1991, 61
15.
Szatmari P, Offord DR, Boyle MIL. Correlates, associated im-pairments and patterns of service utilization of children with attention deficit disorder: findings from the Ontario Child Health Study. J Child Psychol Psychiatry 1989; 30: 205–17PubMedCrossRef
16.
Pope AW, Bierman KL, Mumma GH. Relations between hyper-active and aggressive behavior and peer relations at three elementary grade levels. J Abnorm Child Psychol 1989; 17: 253–67PubMedCrossRef
17.
Cantwell DP, Satterfield JH. The prevalence of academic under-achievement in hyperactive children. J Pediatr Psychol 1978; 3: 168–71CrossRef
18.
Fischer M, Barkley RA, Smallish L, et al. Young adult followup of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002; 30: 463–75PubMedCrossRef
19.
Bagwell CL, Molina BS, Pelham Jr WE, et al. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 2001; 40: 1285–92PubMedCrossRef
20.
Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry 2000, 31
21.
Hansen C, Weiss D, Last CG. ADHD boys in young adulthood: psychosocial adjustment. J Am Acad Child Adolesc Psychiatry 1999; 38: 165–71PubMedCrossRef
22.
Mannuzza S, Klein RG, Bessler A, et al. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155: 493–8PubMed
23.
Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50: 565–76PubMedCrossRef
24.
Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990; 29: 546–57PubMedCrossRef
25.
Fischer M, Barkley R, Fletcher K, et al. The adolescent outcome of hyperactive children diagnosed by research criteria. II: academic, attentional and neuropsychological status. J Consult Clin Psychol 1990; 58: 580–8PubMedCrossRef
26.
Greenfield B, Hechtman L, Weiss G. Two subgroups of hyper-actives as adults: correlations of outcome. Can J Psychiatry 1988; 33: 505–8PubMed
27.
Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 71–8PubMedCrossRef
28.
Voigt RG, Barbaresi WJ, Colligan RC, et al. Occurrence of attention-deficit hyperactivity disorder (ADHD) among indi-viduals with and without mild mental retardation in a popula tion-based birth cohort [abstract]. J Dev Behav Pediatr 2001; 22: 349CrossRef
29.
Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry 2001; 42: 487–92PubMedCrossRef
30.
Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993; 32: 361–8PubMedCrossRef
31.
Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285: 60–6PubMedCrossRef
32.
Woodward LJ, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional difficulties in adolescence. J Am Acad Child Adolesc Psychiatry 2000; 39: 627–34PubMedCrossRef
33.
DiScala C, Lescohier I, Barthel M, et al. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998; 102: 1415–21PubMedCrossRef
34.
Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with atten-tion deficit hyperactivity disorder. Pediatrics 1996; 98: 1089–95PubMed
35.
Lalloo R, Sheiham A. Risk factors for childhood major and minor head and other injuries in a nationally representative sample. Injury 2003; 34: 261–6PubMedCrossRef
36.
Sassi F, Archard L, McDaid D. Searching literature databases for health care economic evaluations: how systematic can we afford to be? Med Care 2002; 40: 387–94PubMedCrossRef
37.
Kelleher KJ, McInemy TK, Gardner WP, et al. Increasing identification of psychosocial problems: 1979-1996. Pediatrics 2000; 105: 1313–21PubMedCrossRef
38.
Hoagwood K, Kelleher KJ, Feil M, et al. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry 2000; 39: 198–206PubMedCrossRef
39.
Rushton J, Bruckman D, Kelleher K. Primary care referral of children with psychosocial problems. Arch Pediatr Adolesc Med 2002; 156: 592–8PubMed
40.
Robison LM, Skaer TL, Sclar DA, et al. Is attention deficit hyperactivity disorder increasing among girls in the US?: trends in the diagnosis and the prescribing of stimulants. CNS Drugs 2002; 16: 129–37PubMedCrossRef
41.
Zito JM, Safer DJ, dosReis S, et al. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Arch Pediatr Med 1999; 153: 1257–63CrossRef
42.
Pastor PN, Reuben C. Attention deficit hyperactivity disorder and learning disability: United States, 1997–98. National Center for Health Statistics Vital and Health Statistics 2002 Series 206, Number 206. Poster presented at the Academy for Health Services Research and Health Policy Annual Research Meeting; 2002 Jun 23–25; Washington, D.C
43.
Bussing R, Zima BT, Perwien AR, et al. Children in special education programs: attention deficit hyperactivity disorder, use of services, and unmet needs. Am J Public Health 1998; 88: 880–6PubMedCrossRef
44.
Miller AR, Lalonde CE, McGrail KM, et al. Prescription of methylphenidate to children and youth: 1990–1996. CMAJ 2001; 165: 1505–6
45.
Brownell MD, Yogendran MS. Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychos_ timulant treatment rates. Can J Psychiatry 2001; 46: 264–72PubMed
46.
Fogelman Y, Kahan E. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel: a controversial issue. Isr Med Assoc J 2001; 3: 925–7PubMed
47.
Schirm E, Tobi H, Zito JM, et al. Psychotropic medication in children: a study from the Netherlands [abstract]. Pediatrics 2001; 108: E25PubMedCrossRef
48.
Reid R, Hakendof P, Prosser B. Use of psychostimulant medication for ADHD in South Australia. J Am Acad Child Adolesc Psychiatry 2002; 41: 906–13PubMedCrossRef
49.
Safer DJ, Malever M. Stimulant treatment in Maryland public schools. Pediatrics 2000; 106: 533–9PubMedCrossRef
50.
Rowland AS, Umbach DM, Stallone L, et al. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health 2002; 92: 231–4PubMedCrossRef
51.
Rushton JL, Whitmire IT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends 1992 to 1998. Arch Pediatr Adolesc Med 2001; 155: 560–5PubMed
52.
Leslie DL, Rosenheck RA, Horwitz SM. Patterns of mental health utilization and costs among children in a privately insured population. Health Serv Res 2001; 36: 113–27PubMed
53.
Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the Medical Expenditure Panel Survey. Arch Pediatr Adolesc Med 2002; 156: 504–11PubMed
54.
Kelleher KJ, Childs GE, Harman IS. Healthcare costs for children with attention-deficit hyperactivity disorder. Econ Neurosci 2001; 3: 60–3
55.
56.
American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J Am Acad Child Adolesc Psychiatry 1997; 36: 85S–121SCrossRef
57.
Zwillich T. Mental health benefits slashed over past decade. Clin Psychiatry News 1998; 26: 1–2
58.
Zwillich T. Mental health benefits continue 10-year decline. Clin Psychiatry News 1999; 27: 31
59.
60.
Katusic SK, Colligan RC, Barbaresi WJ, et al. Potential influence of migration bias in birth cohort studies. Mayo Clin Proc 1998; 73: 1053–61PubMedCrossRef
61.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
62.
Melton III LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 266–74PubMedCrossRef
63.
Miller A, Lee SK, Raina P. Part 1: overview and clinical evaluation of the use of methylphenidate for attention-deficit/ hyperactivity disorder. In: Miller A, Lee SK, Raina P, et al., editors. A review of therapies for attention-deficit/hyperactivity disorder. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998
64.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
65.
Shaffer D, Schwab-Stone M, Fisher P, et al. The diagnostic interview schedule for children-revised versions (DISC-R): preparation, field testing, interrater reliability, and acceptability. J Am Acad Child Adolesc Psychiatry 1993; 32: 643–50PubMedCrossRef
66.
Greenhill LL, Findling RL, Swanson JM, et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder [abstract]. Pediatrics 2002; 109: E39PubMedCrossRef
67.
Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001; 22: 60–73PubMedCrossRef
68.
James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40: 1268–76PubMedCrossRef
69.
Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001; 23: 1904–21PubMedCrossRef
70.
Schachter HM, Pham BA, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? CMAJ 2001; 165: 1475–88PubMed
71.
Jadad AR, Boyle M, Cunningham C, et al. Treatment of Attention deficit/ hyperactivity disorder: evidence report/technology assessment (summary). Rockville (MD): Agency for Healthcare Research and Quality, 1999: 1–341
72.
Klassen A, Miller A, Raina P, et al. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999; 44: 1007–16PubMed
73.
Gillberg C, Melander H, von Knotting AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857–64PubMedCrossRef
74.
Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100: 662–6PubMedCrossRef
75.
Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001; 10: 85–94PubMedCrossRef
76.
Zupancic JAF, Miller A, Raina P, et al. Part 3: economic evaluation of pharmaceutical and psychological/ behavioral therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Raina P, et al., editors. A review of therapies for attention-deficit/hyperactivity disorder [online]. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998. Available from URL: http://​www.​ecohta.​ca/​publications/​pdf/​adhd-techrep.​pdf [Accessed 2003 Oct 16]
77.
Rosser R, Cottee M, Rabin R, et al. Index of health related quality of life. In: Hopkins A, editor. Measures of the quality of life, and the uses to which they may be put. London: Royal College of Physicians of London, 1992: 81–89
78.
79.
Conners CK. Manual for Conners’ rating scales. Toronto, Canada: Multi-Health Systems Inc, 1989
80.
Hoagwood K, Jensen PS, Feil M, et al. Medication management of stimulants in pediatric practice settings: a national perspective. J Dev Behav Pediatr 2000; 21: 322–31PubMedCrossRef
81.
82.
Mannuzza S, Klein RG, Bessler A, et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 1997; 36: 1222–7PubMedCrossRef
83.
Weiss G, Hechtman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985; 24: 211–20PubMedCrossRef
84.
Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Psychiatry 1984; 23: 261–9PubMedCrossRef
85.
Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998; 31: 533–44PubMedCrossRef
86.
Fergusson DM, Lynskey MT, Horwood LJ. Attentional difficulties in middle childhood and psychosocial outcomes in young adulthood. J Child Psychol Psychiatry 1997; 38: 633–44PubMedCrossRef
87.
Schaughency E, McGee R, Raja SN, et al. Self-reported inatten-tion, impulsivity, and hyperactivity at ages 15 and 18 years in the general population. J Am Acad Child Adolesc Psychiatry 1994; 33: 173–84PubMedCrossRef
88.
Wilens TE, Famone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?: a meta-analytic review of the literature. Pediatrics 2003; 111: 179–85PubMedCrossRef
89.
Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder [abstract]. Pediatrics 1999; 104: e20PubMedCrossRef
90.
Earle CC, Tsai IS, Gelber RD, et al. Effectiveness of chemo-therapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001; 19: 1064–70PubMed
91.
McClellan MB, Newhouse JP. Instrumental variables analysis applications in health services research: a special supplement to HSR. Health Serv Res 2000; 35: 1061–202PubMed
92.
Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150: 327–33PubMedCrossRef
93.
Rosenbaum PR, Rubin DB. Reducing bias in observational studies using a subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516–24CrossRef
94.
Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461–94PubMedCrossRef
95.
Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Methodol 2000; 1: 185–202CrossRef
96.
Mrazek DA. A crisis in child psychiatric service delivery: why hasn’t the piper been paid? Mayo Clin Proc 2001; 76: 1078–80PubMedCrossRef
Metadaten
Titel
Economic implications of attention-deficit hyperactivity disorder for healthcare systems
verfasst von
Dr Cynthia L. Leibson
Kirsten Hall Long
Publikationsdatum
01.12.2003
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 17/2003
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200321170-00002